Adults with relapsed B cell acute lymphoblastic leukemia (B-ALL) have a dismal prognosis.
Only those patients able to achieve a second remission with no minimal residual disease (…

The efficacy of chimeric antigen receptor (CAR) T cell therapy against poorly responding
tumors can be enhanced by administering the cells in combination with immune checkpoint …

T cells genetically engineered to express chimeric antigen receptors (CARs) have proven —
and impressive — therapeutic activity in patients with certain subtypes of B cell leukaemia …

Background CD19-specific chimeric antigen receptor (CAR) T cells induce high rates of
initial response among patients with relapsed B-cell acute lymphoblastic leukemia (ALL) and …

Artificial receptors provide a promising approach to target T lymphocytes to tumor antigens.
However, the receptors described thus far produce either an activation or a co-stimulatory …

We report on 16 patients with relapsed or refractory B cell acute lymphoblastic leukemia (B-ALL)
that we treated with autologous T cells expressing the 19-28z chimeric antigen receptor …

A novel approach for the treatment of ovarian cancer includes immunotherapy with genetically
engineered T cells targeted to ovarian cancer cell antigens. Using retroviral transduction, …

Adoptive cell therapy with tumor-targeted T cells is a promising approach to cancer therapy.
Enhanced clinical outcome using this approach requires conditioning regimens with total …

Regional delivery of mesothelin-targeted CAR T-cell therapy followed by pembrolizumab
administration is feasible, safe, and demonstrates evidence of antitumor efficacy in patients …

Chimaeric antigen receptor (CAR) T-cells are T-cells that have been genetically modified to
express an artificial construct consisting of a synthetic T-cell receptor (TCR) targeted to a …